Comparative Pharmacology
Head-to-head clinical analysis: CENOBAMATE versus MYSOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENOBAMATE versus MYSOLINE.
CENOBAMATE vs MYSOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cenobamate is a tetrazole-derived anticonvulsant that modulates GABA A receptors, preferentially inhibiting the persistent sodium current and activating potassium currents (M-current). It also enhances GABA-mediated inhibition and reduces excitatory neurotransmitter release.
Primidone is a barbiturate anticonvulsant that acts by enhancing GABA-A receptor activity and possibly by blocking sodium channels.
Cenobamate 200 mg orally once daily initially, titrated weekly by 50 mg to a target dose of 400 mg once daily; maximum 400 mg/day.
250 mg orally 3 times daily; may increase by 250 mg/day every 3 days; usual maintenance 250 mg 3-4 times daily; maximum daily dose 1500 mg.
None Documented
None Documented
The terminal elimination half-life is approximately 10-17 hours in adults. Steady-state is achieved within 2-3 days. In patients with moderate to severe hepatic impairment, half-life may be prolonged.
Primidone: 5-15 hours (mean 10 hours); PEMA: 10-18 hours; Phenobarbital: 50-120 hours. Steady state achieved in 2-4 weeks due to accumulation of phenobarbital.
Renal excretion accounts for approximately 92% of the administered dose, with 62% as unchanged drug and 30% as metabolites. Fecal excretion is minimal (<2%).
Primidone is excreted primarily in urine; approximately 60-80% as unchanged drug and metabolites (PEMA, phenobarbital), with less than 10% in feces.
Category C
Category C
Anticonvulsant
Anticonvulsant